Diagnosis of Acute Promyelocytic Leukemia
APL must be treated as a medical emergency—start ATRA immediately upon clinical suspicion, even before genetic confirmation, and obtain rapid molecular testing for PML-RARA fusion while simultaneously initiating aggressive coagulopathy management. 1
Immediate Actions Upon Suspicion
Start ATRA Without Delay
- Begin ATRA the moment APL is suspected based on clinical presentation (Level Ib-A evidence) 1
- Do not wait for genetic confirmation to start ATRA
- If genetic testing rules out APL, discontinue ATRA
- Early mortality from hemorrhage is the primary threat—prompt ATRA initiation reduces this risk 1
Recognize the Clinical Picture
Look for these specific features that should trigger immediate APL suspicion:
- Coagulopathy: Low fibrinogen (<150 mg/dL), elevated D-dimer, prolonged PT/aPTT 2
- Cytomorphology: Promyelocytes with heavy granulation and Auer rods on peripheral smear
- Low-to-moderate WBC counts (typically <10 × 10⁹/L in most cases) 2
- Bleeding manifestations: Particularly intracerebral or pulmonary hemorrhage 1
Genetic Confirmation Strategy
Rapid Diagnostic Methods (Use in Parallel)
Molecular confirmation of PML-RARA fusion is mandatory but should not delay ATRA initiation 1. Use these approaches:
For immediate diagnosis (same day to 24 hours):
- FISH (fluorescence in situ hybridization): Highly sensitive and specific, faster than karyotyping 1
- Immunostaining with anti-PML antibodies: Rapid but requires experienced interpretation 1
For definitive diagnosis (must always be performed):
- RT-PCR or RQ-PCR: Gold standard—identifies PML-RARA isoform type and provides baseline for minimal residual disease monitoring 1
- These methods are essential even if FISH/immunostaining already performed 1
Avoid These Pitfalls
- Do not rely on conventional karyotyping alone—it has the highest false-negative rate 1
- Do not perform leukapheresis—it precipitates fatal hemorrhage (Level III-B) 1
- Avoid invasive procedures (central lines, lumbar puncture, bronchoscopy) until coagulopathy resolves 1
Aggressive Coagulopathy Management
Transfusion Thresholds (Start Immediately)
Transfuse daily or more frequently to maintain 1:
- Fibrinogen >100-150 mg/dL (use cryoprecipitate or fibrinogen concentrate)
- Platelets >30-50 × 10⁹/L
- INR <1.5 (use fresh frozen plasma)
Monitoring Requirements
Check at least daily, more often if clinically indicated 1:
- Platelet count
- PT, aPTT, thrombin time
- Fibrinogen level
- Fibrin degradation products
- Continue intensive monitoring until all coagulopathy signs resolve
What NOT to Use
- Do not routinely use heparin or tranexamic acid—benefit remains questionable (Level IV-C) 1
- Reserve anticoagulants/antifibrinolytics for clinical trials only
Special Situation: Hyperleukocytosis (WBC >10 × 10⁹/L)
If WBC >10 × 10⁹/L at presentation:
- Start cytoreductive chemotherapy immediately, even without genetic confirmation 1
- Use idarubicin or daunorubicin (with or without cytarabine) if planning ATRA + chemotherapy regimen
- Use idarubicin 12 mg/m² or gemtuzumab ozogamicin 6-9 mg/m² if planning ATRA + ATO regimen 1
- Consider prophylactic corticosteroids to reduce differentiation syndrome risk 1
Important distinction: If WBC rises above 10 × 10⁹/L after starting ATRA/ATO, this represents differentiation—do not reclassify as high-risk 1
Optimal Care Setting
Manage patients in centers with 1:
- Experienced multidisciplinary team
- Rapid access to genetic diagnosis (ideally <24 hours)
- 24/7 availability of blood products
- Immediate access to ATRA, ATO, and chemotherapy
Recent quality improvement data show molecular diagnosis turnaround time can be reduced to 0.64 days with optimized workflows and reflex testing protocols 2.
Additional Molecular Testing
Do NOT routinely test for 1:
- FLT3-ITD mutations
- WT1, NRAS, KRAS mutations
- These have uncertain prognostic significance and should not guide initial management